On 23 April 2026, Les Laboratoires Servier finalized its acquisition of Day One Biopharmaceuticals (NASDAQ: DAWN) following a definitive merger agreement signed on 6 March 2026. Under the terms of the transaction, Servier acquired all outstanding shares of Day One for $21.50 per share in cash, representing a total equity value of approximately $2.5 billion (and an enterprise value of ~$2.2 billion net of cash). The acquisition price represented a 68 percent premium over Day One's closing share price on 5 March 2026 and an 86 percent premium over its 30-day volume-weighted average price (VWAP). Servier fully funded the transaction using balance-sheet cash without external debt financing.
The cornerstone asset of the acquisition is Ojemda (tovorafenib)—an oral, selective, central nervous system (CNS)-penetrant type II RAF (pan-RAF) inhibitor. Approved by the U.S. FDA in April 2024 for pediatric patients aged 6 months and older with relapsed or refractory pediatric low-grade glioma (pLGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation, Ojemda represents the first and only approved monotherapy targeted treatment engineered specifically for this population. Beyond its FDA approval and a positive CHMP opinion from the European Medicines Agency, tovorafenib achieved an historic regulatory milestone on 4 May 2026 when the Coordination Group endorsed the very first EU Joint Clinical Assessment (JCA) under Regulation (EU) 2021/2282 — led by Ireland's NCPE with Germany's IQWiG producing the report as co-assessor — establishing a crucial reference point for European pricing and reimbursement. (Outside the United States, tovorafenib is held by Ipsen; Servier's acquisition covers the U.S. franchise and Day One's pipeline.)
+---------------------------------------------------------------------------------------------------+
| SERVIER / DAY ONE ACQUISITION & TOVORAFENIB REGULATORY MILESTONES |
+---------------------------------------------------------------------------------------------------+
| |
| TRANSACTION TERMS (CLOSED APRIL 23, 2026) |
| • Purchase Price: $21.50 per Share (All-Cash) • Equity Value: ~$2.5 Billion |
| • Premium: +68% over 1-Day Close / +86% 30-Day VWAP • Funding: Existing Balance-Sheet Cash |
| |
| LEAD ASSET: OJEMDA (TOVORAFENIB) |
| • Class: Oral Type II RAF (Pan-RAF) Kinase Inhibitor (Avoids Paradoxical MAPK Activation) |
| • Indication: Relapsed/Refractory Pediatric Low-Grade Glioma (pLGG) with BRAF Alteration |
| • FDA Status: Approved (April 2024, Age >= 6 Months) |
| • EMA Status: Positive CHMP Opinion (Q1 2026) |
| • EU HTA Status: Completed 1st EU Joint Clinical Assessment (NCPE Ireland lead / IQWiG co-assessor, 4 May 2026) |
| |
| PIPELINE INCLUSIONS |
| • Emi-Le (emiltatug ledadotin): B7-H4-Targeted Antibody-Drug Conjugate (ADC), Breakthrough for ACC |
| • DAY301: PTK7-Targeted Antibody-Drug Conjugate (ADC) in Adult/Pediatric Solid Tumors |
+---------------------------------------------------------------------------------------------------+
What were the exact terms and timing of the Servier-Day One deal?
For biopharma business development (BD) and M&A leads, the transaction structure highlights Servier's aggressive expansion into rare oncology and targeted neuro-oncology therapies:
| Transaction Attribute | Verified Deal Parameter | Strategic Rationale |
|---|---|---|
| Target Company | Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) | U.S. commercial-stage pediatric oncology biotech |
| Acquiring Entity | Les Laboratoires Servier (Servier Group, France) | Global governance foundation expanding U.S. oncology footprint |
| Per Share Consideration | $21.50 per share in cash | Clean all-cash tender offer without contingent value rights (CVRs) |
| Total Equity Value | ~$2,500 Million ($2.5 Billion) | Based on ~116 million fully diluted shares outstanding |
| Enterprise Value | ~$2,200 Million ($2.2 Billion) | Net of Day One's ~$300M cash and short-term investments |
| 1-Day Closing Premium | +68.0% | Premium over $12.80 closing price on March 5, 2026 |
| 30-Day VWAP Premium | +86.0% | Premium over $11.56 30-day volume-weighted average |
| Financing Method | Existing cash reserves | No debt covenants or syndicated loan dependencies |
| Announcement Date | March 6, 2026 | Definitive merger agreement executed |
| Transaction Close | April 23, 2026 | Tender offer completed; second-step merger to acquire remaining shares |
The deal terms reflect a premium valuation driven by Ojemda's commercial de-risking in the United States and immediate ex-U.S. expansion potential. By avoiding complex Contingent Value Right (CVR) structures—which often delay clinical integration—Servier secured immediate, unencumbered ownership of Day One's commercial operations, sales force, and pipeline assets.
How does tovorafenib (Ojemda) work and what did its pivotal data show?
Pediatric low-grade glioma (pLGG) is the most common brain tumor diagnosed in children, accounting for approximately 30 to 40 percent of all pediatric CNS neoplasms. Mitogen-Activated Protein Kinase (MAPK) pathway alterations drive virtually all pLGG cases, with BRAF gene alterations occurring in over 75 percent of patients. The most frequent driver is the KIAA1549-BRAF gene fusion (present in ~60–70% of pLGG), followed by the BRAF V600E point mutation (~10–15%).
RAF INHIBITOR MECHANISTIC COMPARISON
TYPE I RAF INHIBITORS (e.g., Dabrafenib) TYPE II RAF INHIBITORS (Tovorafenib)
┌──────────────────────────────────────┐ ┌──────────────────────────────────────┐
│ • Binds monomeric active BRAF │ │ • Binds inactive conformation (DFG- │
│ • Monomer-selective │ │ out) of monomer AND dimer RAF │
│ • In BRAF-fusion tumors: triggers │ │ • Inhibits wild-type, fusion & mutant│
│ PARADOXICAL MAPK ACTIVATION │ │ • AVOIDS paradoxical activation │
│ • Requires MEK co-inhibition │ │ • Monotherapy effective in fusions │
└──────────────────────────────────────┘ └──────────────────────────────────────┘
The Type II RAF Inhibitor Advantage
First-generation Type I RAF inhibitors (such as dabrafenib or vemurafenib) selectively bind the active monomeric state of BRAF V600E mutants. However, when exposed to BRAF fusions (KIAA1549-BRAF) or wild-type CRAF, Type I inhibitors induce paradoxical activation of the MAPK pathway—hyper-activating ERK signaling and accelerating tumor growth.
Tovorafenib is an oral Type II RAF inhibitor. It binds to the inactive conformation (DFG-out) of both monomeric and dimeric RAF complexes (BRAF and CRAF). By inhibiting dimeric RAF complexes without triggering paradoxical activation, tovorafenib can be administered as a single-agent therapy in patients harboring BRAF fusions without requiring a combination MEK inhibitor (such as trametinib).
Pivotal Clinical Trial Evidence: FIREFLY-1
The FDA accelerated approval and European filings were supported by the phase 2 FIREFLY-1 trial (NCT04775485), an open-label, single-arm study of tovorafenib monotherapy in patients aged 6 months to 25 years with relapsed or progressive pLGG harboring an activating BRAF alteration. The primary efficacy analysis came from arm 1 (77 treated patients):
| Endpoint | FIREFLY-1 Arm 1 Results | Clinical & Regulatory Impact |
|---|---|---|
| Overall Response Rate (ORR), RANO-HGG (primary) | 67% (12 complete + 34 partial responses) | Primary endpoint met; independent review committee–assessed |
| Complete Response (CR) | 17% (12 patients) | High rate of total radiological tumor clearance in pediatric CNS |
| Partial Response (PR) | 49% (34 patients) | Durable tumor shrinkage across BRAF fusions and V600E mutations |
| Stable Disease (SD) | 26% (18 patients) | Clinical benefit rate (CBR) reached 93% |
| ORR by RAPNO-LGG criteria (secondary) | 51% | Confirmed across multiple response-assessment frameworks |
| Median Duration of Response (DoR) | 16.6 months | Durable disease control in heavily pretreated pediatric patients |
| Median Time to Response (TTR) | 3.0 months | Rapid onset of neurological and visual improvement |
Tovorafenib demonstrated manageable safety, with the most common treatment-emergent adverse events including hair color changes, anemia, elevated creatine kinase, fatigue, and maculopapular rash. Importantly, tovorafenib exhibited low rates of treatment-discontinuation due to adverse events, a critical factor for long-term administration in pediatric patients.
Who else is competing in pediatric low-grade glioma, and how crowded is the trial landscape?
Prior to tovorafenib's approval, customary systemic management for relapsed pLGG relied on multi-agent intravenous chemotherapy (carboplatin, vincristine, vinblastine) or repeated surgical resection, which carries high risks of permanent neurological, endocrine, or visual impairment.
The targeted competitive landscape in pLGG features two dominant approaches:
+---------------------------------------------------------------------------------------------------+
| PEDIATRIC LOW-GRADE GLIOMA (pLGG) COMPETITIVE MATRIX |
+---------------------------------------------------------------------------------------------------+
| |
| DABRAFENIB + TRAMETINIB (Novartis) TOVORAFENIB / OJEMDA (Servier / Day One) |
| • FDA Approved (BRAF V600E Mutation Only) • FDA Approved (BRAF Fusions & BRAF V600E) |
| • Dual-Drug Regimen (BRAF + MEK Inhibitor) • Single-Agent Monotherapy (Type II Pan-RAF) |
| • Restricted to V600E (~10-15% of pLGG) • Broad Coverage (~75%+ of all pLGG) |
| • Twice-Daily Oral Dosing • Once-Weekly Oral Powder / Tablet Dosing |
| |
| PIVOTAL PHASE 3 HEAD-TO-HEAD BATTLE |
| • FIREFLY-2 / LOGGIC (NCT05566795): Phase 3 Randomised Trial Comparing Tovorafenib vs |
| Conventional Physician-Choice Chemotherapy (Carboplatin-Vincristine or Vinblastine) |
+---------------------------------------------------------------------------------------------------+
- Novartis (Dabrafenib + Trametinib): Approved by the FDA for pediatric patients with BRAF V600E-mutated low-grade glioma. While effective, this combination is strictly limited to the BRAF V600E mutation (~10–15% of pLGG) and cannot treat KIAA1549-BRAF fusions due to paradoxical activation. Furthermore, it requires managing a dual-drug toxicity profile.
- Servier / Day One (Tovorafenib): Covers both BRAF fusions and BRAF V600E mutations, giving Ojemda access to over 75 percent of all pLGG patients. Its once-weekly oral administration (available as tablets or oral suspension) offers superior convenience over twice-daily regimens.
To move from the relapsed setting into first-line therapy, Servier is advancing the randomized phase 3 FIREFLY-2 / LOGGIC trial (NCT05566795). Now fully enrolled with 418 patients across international sites (the largest front-line pLGG study ever conducted, with topline data expected by mid-2027), FIREFLY-2 directly compares once-weekly tovorafenib monotherapy against physician-choice chemotherapy (carboplatin/vincristine or vinblastine). A positive readout in FIREFLY-2 would establish tovorafenib as a preferred initial systemic option across pediatric neuro-oncology centers.
What pediatric formulation and distribution realities shape Ojemda's access?
Delivering precision neuro-oncology therapies to pediatric populations introduces specialized formulation, dispensing, and specialty-pharmacy requirements that set Ojemda apart from adult oral oncology drugs:
- Dual Dosage Forms for Young Patients: Ojemda is supplied as both 100 mg film-coated tablets and an oral suspension powder (25 mg/mL). For pediatric patients under 6 years of age or those with swallowing difficulties or enteral feeding tubes (g-tubes/j-tubes), the oral suspension allows precise weight-based dosing (380 mg/m² once weekly, not to exceed 600 mg once weekly).
- Once-Weekly Compliance Advantage: Because pediatric pLGG management often extends for 12 to 24 months, a once-weekly oral schedule significantly reduces treatment burden compared to daily or twice-daily oral regimens, minimizing missed doses during school schedules.
- Specialty Pharmacy Distribution: In the United States, Servier distributes Ojemda through a restricted specialty pharmacy network coupled with the Day One Companion patient support hub, providing co-pay assistance, foundation assistance navigation, and home delivery of reconstituted oral suspension kits.
Why was tovorafenib the first completed EU Joint Clinical Assessment?
A crucial element of the Servier acquisition is Ojemda's position in European regulatory history. On 4 May 2026, the HTA Coordination Group endorsed the first EU Joint Clinical Assessment (JCA) under Regulation (EU) 2021/2282 for tovorafenib. The assessment was led by Ireland's National Centre for Pharmacoeconomics (NCPE), with Germany's Institute for Quality and Efficiency in Health Care (IQWiG) producing the report as co-assessor; outside the United States, tovorafenib is held by Ipsen, which submitted the JCA dossier.
This completion yielded key operational lessons for biopharma access leads:
- PICO Scoping Alignment: Because pLGG is a rare pediatric cancer, the assessment scope consolidated eight PICOs across three populations and accepted single-arm trial data (FIREFLY-1) supported by historical chemotherapy context.
- EU HTA IT Platform Integration: The tovorafenib JCA dossier was successfully processed, evaluated, and finalized via the central EU HTA IT Platform, proving that joint assessments can meet statutory deadlines — HTACG endorsement followed roughly 10 days after the European Commission's conditional authorization.
- National P&R Benchmark: The published JCA clinical report now serves as the shared clinical basis for national pricing negotiations across EU member states; in Germany's AMNOG process, for example, the manufacturer may refer to the European dossier, though national bodies retain the right to supplement with additional clinical data.
What does the Day One pipeline add to Servier's oncology portfolio?
While tovorafenib represents the immediate commercial engine, Servier's $2.5 billion purchase also secures two antibody-drug conjugate (ADC) pipeline programs:
1. Emi-Le (Emiltatug Ledadotin)
Emi-Le is a potentially first-in-class ADC directed against B7-H4, a cell-surface antigen highly expressed in adenoid cystic carcinoma (ACC) as well as in triple-negative breast cancer, endometrial, and ovarian cancers. Built on the Dolasynthen platform with a target-optimized drug-to-antibody ratio (DAR 6) and a proprietary auristatin-F HPA payload with a controlled bystander effect, Emi-Le originated at Mersana Therapeutics (as XMT-1660) and entered Day One's pipeline through its acquisition of Mersana. The FDA granted Emi-Le Breakthrough Therapy designation for ACC in May 2026 and Fast Track designations for advanced triple-negative breast cancer and HER2-low/HER2-negative breast cancer following a topoisomerase-I ADC. Early Phase 1 data showed confirmed objective responses across multiple tumor types.
2. DAY301 (PTK7-Targeted ADC)
DAY301 is a potentially first-in-class ADC targeting protein tyrosine kinase 7 (PTK7), which is consistently and highly expressed on the cell surface of multiple adult and pediatric cancers — including platinum-resistant ovarian cancer, triple-negative breast cancer, non-small cell lung cancer, neuroblastoma, and osteosarcoma. Designed to maximize therapeutic index and overcome limitations of earlier-generation ADCs, DAY301 has shown antitumor activity in preclinical models and is in early Phase 1 evaluation (DAY301-001).
Biopharma strategists analyzing neuro-oncology access should cross-reference our vorasidenib IDH glioma access landscape to see how Servier is building a dual franchise across adult IDH-mutant glioma (Voranigo) and pediatric RAF-altered glioma (Ojemda).
Furthermore, access leads evaluating ADC transaction structures should review our antibody-drug conjugate clinical trials by the numbers, and compare Servier's deal terms with our deal anatomy of the Neurocrine-Soleno acquisition for benchmarks on rare-disease buyout premiums. Finally, teams navigating European market access should cross-link to our comprehensive guide to EU Joint Clinical Assessments under the 2026 HTA Regulation to trace how tovorafenib's milestone JCA reshapes European launch timing.
Frequently Asked Questions
Is Ojemda (tovorafenib) approved in the EU?
Yes. Following a positive CHMP opinion, Ipsen — which holds the ex-U.S. rights — secured European Commission conditional marketing authorization for tovorafenib in April 2026 for relapsed or refractory pediatric low-grade glioma harboring BRAF alterations. National pricing and reimbursement proceedings are now supported by the completed EU Joint Clinical Assessment, which the Coordination Group endorsed on 4 May 2026.
How much did Servier pay per share and what was the premium?
Servier paid $21.50 per share in cash for Day One Biopharmaceuticals, representing a total equity value of approximately $2.5 billion. The purchase price represented a 68 percent premium over Day One's closing price on 5 March 2026 and an 86 percent premium over its 30-day volume-weighted average price.
What is a type II RAF or pan-RAF inhibitor and why does it matter for pediatric glioma?
Type II RAF inhibitors bind to the inactive conformation of both monomeric and dimeric RAF complexes (BRAF and CRAF). Unlike first-generation Type I RAF inhibitors (e.g., dabrafenib), Type II inhibitors do not cause paradoxical activation of the MAPK pathway in tumors harboring BRAF fusions (KIAA1549-BRAF). This enables tovorafenib to be administered as a single-agent monotherapy across both BRAF fusions and BRAF V600E mutations.
Who holds ex-US rights to tovorafenib?
Outside the United States, tovorafenib (Ojemda) is held by Ipsen, which licensed ex-U.S. rights from Day One before the Servier acquisition and separately secured European Commission conditional marketing authorization in April 2026. Servier's acquisition covers the U.S. commercial franchise and Day One's pipeline; it does not transfer the ex-U.S. tovorafenib rights to Servier.
Sources
- Les Laboratoires Servier & Day One Biopharmaceuticals: Servier Completes Acquisition of Day One Biopharmaceuticals to Expand Global Leadership in Rare Pediatric Oncology. Joint Press Release, 23 April 2026. Accessible at:
https://www.servier.com/en/news/ - U.S. Securities and Exchange Commission (SEC): Day One Biopharmaceuticals, Inc. Schedule TO / Tender Offer Statement (Form SC TO-T). Filed by Les Laboratoires Servier, 18 March 2026.
- U.S. Food and Drug Administration (FDA): FDA Approves Tovorafenib (Ojemda) for Relapsed or Refractory Pediatric Low-Grade Glioma. Center for Drug Evaluation and Research (CDER). Accessible at:
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tovorafenib-relapsed-or-refractory-pediatric-low-grade-glioma - ClinicalTrials.gov: FIREFLY-1: A Phase 2 Study of Tovorafenib (DAY101) in Pediatric Patients With Relapsed or Progressive Low-Grade Glioma (NCT04775485). U.S. National Library of Medicine. Accessible at:
https://clinicaltrials.gov/study/NCT04775485 - ClinicalTrials.gov: FIREFLY-2 / LOGGIC: A Phase 3 Study of Tovorafenib Monotherapy Versus Conventional Chemotherapy in First-Line Pediatric Low-Grade Glioma (NCT05566795). U.S. National Library of Medicine. Accessible at:
https://clinicaltrials.gov/study/NCT05566795 - Institute for Quality and Efficiency in Health Care (IQWiG): A significant step in the new EU HTA process: first assessment completed (tovorafenib, led by Ireland's NCPE with IQWiG as co-assessor). Press Release, 4 May 2026.
- Nature Medicine: The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial (arm 1: ORR 67%, 12 CR / 34 PR, CBR 93%, median DoR 16.6 months). Accessible at:
https://www.nature.com/articles/s41591-023-02668-y - Day One Biopharmaceuticals / Servier: Pipeline — Emi-Le (emiltatug ledadotin, B7-H4-directed ADC) and DAY301 (PTK7-targeted ADC); Emi-Le FDA Breakthrough Therapy designation for ACC (May 12, 2026). Accessible at:
https://www.dayonebio.com/our-science/pipeline - Clinical Trials Arena: Ipsen's Ojemda (tovorafenib) secured European Commission approval (April 2026); ex-U.S. rights held by Ipsen. Accessible at:
https://www.clinicaltrialsarena.com/features/eus-joint-clinical-assessment-system-still-finding-its-footing
